About Us

Atul R. Mahableshwarkar, MD, DFAPA

Atul R. Mahableshwarkar, MD, DFAPA – Chief Medical Officer and Senior Vice President of Drug Development

Dr. Atul Mahableshwarkar leads the Clinical Affairs, Pharmacovigilance, Regulatory Affairs and Quality Assurance divisions at Emalex Biosciences.

Dr. Mahableshwarkar is a board-certified adult psychiatrist who was formerly an Associate Professor and Vice Chair of the Department of Psychiatry and Behavioral Sciences at the Chicago Medical School of Rosalind Franklin University. Previously, he also led mental health services at the former North Chicago VA Medical Center, providing care to patients with psychiatric disorders.

Dr. Mahableshwarkar has nearly two decades of drug development experience. Prior to joining Emalex, he served as Vice President of Clinical Development at Revance Therapeutics and BlackThorn Therapeutics; Senior Medical Director at Takeda Development Center Americas; as well as Director of Clinical Development at GlaxoSmithKline and Janssen Pharmaceuticals. Dr. Mahableshwarkar has designed and conducted global clinical trials in Alzheimer’s disease, anxiety disorders, bipolar disorder, major depression, Parkinson’s Disease and schizophrenia and led the development program resulting in the approval of a novel antidepressant. He is a founding member of the International Society for CNS Clinical Trials and Methodology (ISCTM) and the CNS Summit.

Dr. Mahableshwarkar is a graduate of the Armed Forces Medical College in India and completed a residency in adult psychiatry and a fellowship in neuropsychiatry at the Chicago Medical School of Rosalind Franklin University.